Sars-Cov-2 (Covid-19) Ad26 Vaccine, Recombinant Dosage
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for COVID-19
FOR INVESTIGATIONAL USE ONLY
Primary series: 0.5 mL IM once
Booster Dose: 0.5 mL IM, at least 2 months after completing a primary series
Comments:
- This drug is not approved by the US FDA to prevent coronavirus disease 2019 (COVID-19). The US FDA has issued an Emergency Use Authorization (EUA) for the use of this drug to prevent COVID-19.
- No data are available regarding the use of this vaccine to complete a COVID-19 vaccine series initiated with another vaccine.
Use: For active immunization to prevent COVID-19 due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for whom other US FDA-authorized or approved COVID-19 vaccines are not accessible or clinically appropriate and in those who elect to receive this vaccine because they would otherwise not receive a COVID-19 vaccine
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
US BOXED WARNING:
THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME (TTS):
- This vaccine can cause TTS, which may be life-threatening.
- TTS may involve thrombosis at unusual locations for a thrombus (e.g., central artery/vein, cerebral vein, extremity artery, visceral artery/vein) or in an extremity vein or pulmonary artery.
- Among reported cases of TTS following administration of this vaccine, symptoms began approximately 1 to 2 weeks after vaccination.
- The clinical course of TTS following administration of this vaccine shares features with autoimmune heparin-induced thrombocytopenia (HIT). In patients with suspected TTS, the use of heparin may be harmful, and alternative treatments may be needed.
- Vaccine recipients should be instructed to seek immediate medical attention for chest pain, leg pain, neurological symptoms (e.g., severe/persistent headaches or blurred vision), persistent abdominal pain, petechiae beyond the site of vaccination, or shortness of breath.
- This vaccine should not be administered to individuals with a history of thrombosis with thrombocytopenia following this vaccine or any other adenovirus-vectored COVID-19 vaccine.
CONTRAINDICATIONS:
- Patients with a severe allergic reaction (e.g., anaphylaxis) to any of the ingredients
- Those with a history of TTS following administration of this or any other adenovirus-vectored COVID-19 vaccine
Safety and efficacy have not been established in patients younger than 18 years.
Dialysis
Data not available
Other Comments
Administration advice:
- For IM administration only.
Storage requirements:
- Prior to first puncture of vial, store at 2C to 8C (36F to 46F) and protect from light; do not freeze.
- Unpunctured vials may be stored between 9C to 25C (47F to 77F) for up to 12 hours.
- The manufacturer initially stores vials frozen and ships at 2C to 8C (36F to 46F); if it is still frozen upon arrival, thaw at 2C to 8C (36F to 46F).
- If needed immediately, thaw at room temperature (maximally 25C [77F]).
- Note: A carton of 10 vials will take approximately 2 hours to thaw, an individual vial will thaw in approximately 1 hour.
- Do not refreeze once thawed.
- After first puncture of vial AND once the first dose is withdrawn, store between 2C to 8C (36F to 46F) for up to 6 hours, or at room temperature (maximally 25C [77F]) for up to 2 hours; discard the open vial if not used within the time frames.
Reconstitution/preparation techniques:
- The product is a colorless to slightly yellow, clear to very opalescent suspension; do not use if discolored or particulate matter is present.
- Before withdrawing each dose, carefully mix vial contents by swirling gently in an upright position for 10 seconds; DO NOT SHAKE.
- Each vial contains multiple doses; do not pool excess vaccine from multiple vials.
- Once opened, record the date and time of first use on the vaccine vial label.
General:
- This vaccine is preservative free.
- Appropriate medical management of immediate allergic reactions must be available for acute anaphylactic reactions.
Patient advice:
- Read the Fact Sheet for Recipients and Caregivers.
More about sars-cov-2 (covid-19) ad26 vaccine, recombinant
Patient resources
Other brands
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.